Phase I trial of anti-CD74 (hLL1) Antibody Therapy in B-cell malignancies

Update: this study is closed to enrollment. 

Previous expericence with antibody therapy in both non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) suggests the need for further exploration of new antibody treatments for these diseases.

This is a Phase I, open-label study being conducted in patients with recurrent non-Hodgkin’s lymphoma or chronic lymphocytic leukemia who have progressed after at least one prior standard treatment.

Click here to for the clinical and research profile of John Leonard, MD, the physician leading the study.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: